A basic market inefficiency has created a massive opportunity for startup investors interested in medical technology and drug development startups. And angel investors savvy enough to understand what’s going on have a rare opportunity to invest in medtech startups with massive upside that have been significantly de-risked. Historically, early stage startups developing new drugs, medical compounds and medical devices have struggled to raise capital. They’re “too early” for venture capitalists (VCs). No…